Diagnostic Solutions Laboratory issued the following announcement on Feb. 21.
Diagnostic Solutions Laboratory (DSL) continues its innovative vision to transform and improve personalized medicine by introducing its first DNA SNP test, GenomicInsight™ Genomic Health Profile powered by Opus23 Explorer™, a proprietary version of DataPunk's Opus23 informatics software, conceived, developed, and coded by Dr. Peter D'Adamo, Distinguished Professor of Clinical Sciences, University of Bridgeport.
GenomicInsight analyzes variations occurring within a patient's genetic code. We are born with these variations, also known as single nucleotide polymorphisms (SNPs). However, they can be influenced by diet and lifestyle changes, nutraceutical therapies, and other environmental factors; a science we understand today as epigenetics.
Tony Hoffman, Chief Executive Officer of Diagnostic Solutions, is excited to bring GenomicInsight to market because "It is a game-changer in the field of DNA testing. Until now, clinicians have had restricted access to a patient's SNP data, relying on limited consumer panels. Now, DSL is combining its high-complexity DNA technology with the powerful Opus23 Explorer software to give practitioners unparalleled access to critical data points that reveal a patient's genomic individuality."
Mr. Hoffman goes on to say that, "The role genomics play in overall health is widely recognized and GenomicInsight is a clinical diagnostic tool that provides practitioners with information that revolutionizes the field of personalized medicine."
GenomicInsight measures nearly one million SNPs and reports on over 5,200 (SNPs) that span over a dozen areas of patient health. Results, in the form of SNP data files, are synthesized by Opus23 Explorer's automated information (AI) software technology.
The Opus23 Explorer interactive dashboard uses the latest medical literature to provide relevant information on nutraceuticals, nutritional supplements, diet, and lifestyle interventions that can proactively influence a patient's SNPs to reduce or prevent disease risk. Furthermore, pharmacogenomic results included in the profile allow practitioners to predict the efficacy of select pharmaceuticals tailored to the individual's genetic make-up. Dr. D'Adamo has described the Opus23 suite of bioinformatic apps as "generative software," tools that, by their very design, "relieve the clinician of the more burdensome demands of Big Data while still providing the grist for high-information value decisions."
GenomicInsight Powered by Opus23 Explorer includes:
- An interactive dashboard allowing practitioners to curate results from select areas of health including detoxiﬁcation, cardiovascular health, methylation, HPA-axis, metabolic syndrome, mitochondrial health, pharmacogenomics, nutrigenomics, estrogen metabolism, sex hormones, aging, and autoimmunity
- Medical datasets and biomedical literature updated in "real-time,"including PubMed
- Evidence-based therapeutic recommendations
Dr. David Brady, the Chief Medical Officer of Diagnostic Solutions Laboratory, says, "GenomicInsight is truly an advancement in personalized precision medicine at the point of clinical care. The Opus23 Explorer software provides unprecedented insight into the unique characteristics of the individual. Practitioners can now benefit from the automated evidence-based curation of the patient's genomic information while remaining directly involved in the clinical contextualization of the information as they determine personalized therapeutic interventions that have the highest probability of moving the dial on improving the patient's state of health and vitality."
GenomicInsight powered by Opus23 Explorer launches today, February 21, 2019.
About Diagnostic Solutions Laboratory:
Diagnostic Solutions Laboratory was founded to bridge the gap between healthcare providers and the clinical laboratory. Our commitment is to serve the clinical needs of the healthcare provider with cutting-edge laboratory medicine by utilizing proven methodologies that are accurate and reliable. By working with experienced clinicians and opinion leaders throughout multiple medical disciplines, we build assays that are clinically relevant and provide actionable results.
Diagnostic Solutions Laboratory is the innovator of the GI Microbial Assay Plus (GI-MAP™), the first DNA-based stool test that utilizes cutting-edge, quantitative PCR (qPCR) technology.
Learn more about GenomicInsight and other DNA-based diagnostic testing offered by Diagnostic Solutions Laboratories at https://www.diagnosticsolutionslab.com.
Original source can be found here.